Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vadhan-Raj, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vadhan-Raj, S.

Stem Cells, Vol 12, 253-261, Copyright © 1994 by AlphaMed Press

REVIEWS

PIXY321 (GM-CSF/IL-3 fusion protein): biology and early clinical development

S Vadhan-Raj
Department of Clinical Immunology and Biological Therapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) are functionally related hematopoietins with overlapping but distinct hematopoietic effects. GM-CSF supports more myeloid progenitor cells, whereas IL-3 promotes more erythroid, megakaryocytic and multipotential progenitor cells. Their complementary in vivo biological effects and cross competition for receptor binding prompted the development of PIXY321, a synthetic hybrid protein of GM- CSF and IL-3. PIXY321 binds to cell lines expressing specific receptors for either ligand, and it exhibits enhanced biological activity in human hematopoietic progenitor cell assays. In preclinical studies, PIXY321 has been shown to accelerate both neutrophil and platelet recovery in rhesus monkeys subjected to sublethal irradiation. Based on these preclinical observations, clinical trials have been initiated examining the therapeutic potential of this agent in ameliorating treatment- or disease-related hematopoietic suppression. The early results indicate that PIXY321 can stimulate multilineage hematopoiesis in vivo and enhance neutrophil and platelet recovery following chemotherapy and bone marrow transplantation (BMT). These results suggest that PIXY321 elicits the biological effects of both its component cytokines and represents a novel means of delivering two independent but interactive cytokines in combination.


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
J. C.L. Schuh and P. J. Morrissey
Development of a Recombinant Growth Factor and Fusion Protein: Lessons from GM-CSF
Toxicol Pathol, January 1, 1999; 27(1): 72 - 77.
[Abstract] [PDF]

Home page
 Stem CellsHome page
P. Lefebvre, J.N. Winter, A.W. Rademaker, C. Goolsby, and I. Cohen
In Vitro Production of Megakaryocytes from PIXY321 versus GM-CSF-Mobilized Peripheral Blood Progenitor Cells
Stem Cells, March 1, 1997; 15(2): 112 - 118.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.stemcellsportal.com/
Copyright © 1994 by AlphaMed Press.